Evaluating Oral Azacitidine for the Treatment of Low- or Intermediate-Risk Myelodysplastic Syndromes

FEATURING:

Guillermo Garcia-Manero, MD
Professor, Department of Leukemia, Division of Cancer Medicine
Chief, Section of Myelodysplastic Syndromes, Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Please join Guillermo Garcia-Manero, MD, from MD Anderson Cancer Center, as he describes the study design of a new phase 2/3 study evaluating oral azacitidine for the treatment of myelodysplastic syndromes.